PharmaCyte Biotech
PMCB
29 hedge funds and large institutions have $3.47M invested in PharmaCyte Biotech in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 13 reducing their positions, and 6 closing their positions.
0% more funds holding
Funds holding: 29 → 29 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
13% less ownership
Funds ownership: 20.23% → 7.23% (-13%)
66% less capital invested
Capital invested by funds: $10.2M → $3.47M (-$6.75M)
77% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 13
93% less call options, than puts
Call options by funds: $27K | Put options by funds: $366K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$131K |
| 2 |
Renaissance Technologies
New York
|
+$77.6K |
| 3 |
Bank of New York Mellon
New York
|
+$49.8K |
| 4 |
CL
CSS LLC
Chicago,
Illinois
|
+$39.6K |
| 5 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$2.86K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Ayrton Capital
Westport,
Connecticut
|
-$2.26M |
| 2 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$1.71M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.55M |
| 4 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
-$808K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$311K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
NA
26
NewEdge Advisors
New Orleans,
Louisiana
| $6 | – | – | – |
|
|
CWA
27
Carolina Wealth Advisors
Myrtle Beach,
South Carolina
| $6 | +$6 | +2 | New |
|
28
Fidelity Investments
Boston,
Massachusetts
| $3 | +$3 | +1 | New |
|
|
29
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$311K | -106,886 | Closed |
|
30
State Street
Boston,
Massachusetts
| – | -$182K | -62,600 | Closed |
|
31
T. Rowe Price Associates
Baltimore,
Maryland
| – | -$75K | -25,600 | Closed |
|
32
Belvedere Trading
Chicago,
Illinois
| – | -$20.8K | -7,135 | Closed |
|
|
TRCT
33
Tower Research Capital (TRC)
New York
| – | -$1K | -505 | Closed |
|
|
TWA
34
TCI Wealth Advisors
Tucson,
Arizona
| – | -$9 | -3 | Closed |
|
PMCB Hedge Fund Activity: Q2 2023 in Review
29 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q2 2023, worth a combined $3.47M — down 66% from $10.2M a quarter earlier.
Fund positioning in PMCB was balanced in Q2 2023: 6 funds opened new positions, 6 closed out, 3 added to existing stakes and 13 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $131K. The largest seller was Ayrton Capital, cutting an estimated $2.26M.
- 29 institutional investors held PharmaCyte Biotech (PMCB) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $3.47M of PharmaCyte Biotech stock for Q2 2023, down 66% quarter-over-quarter.
- 6 funds opened new PharmaCyte Biotech positions in Q2 2023 and 6 closed out, a net change of 0 holders.
- The largest PharmaCyte Biotech buyer in Q2 2023 was Geode Capital Management, an estimated $131K added.
- The largest PharmaCyte Biotech seller in Q2 2023 was Ayrton Capital, an estimated $2.26M sold.
Based on aggregated 13F filings for Q2 2023.